Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 5/2015

01-09-2015 | Clinical Investigation

Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis

Authors: Jeong Hun Bae, Sung Chul Lee

Published in: Japanese Journal of Ophthalmology | Issue 5/2015

Login to get access

Abstract

Purpose

To evaluate the outcomes of intravitreal liposomal amphotericin B (L-AmB) for treatment of endogenous candida endophthalmitis.

Methods

Medical records of four patients with endogenous candida endophthalmitis treated with intravitreal L-AmB injection alone or combined with vitrectomy were reviewed.

Results

Endogenous candida endophthalmitis developed in two patients after gastrointestinal surgery, in one patient with sepsis, and in one patient undergoing systemic chemotherapy for metastatic breast cancer. Three eyes of two patients exhibited toxic uveitis following repetitive intravitreal injection of amphotericin B deoxycholate (AmB-D, 10 μg/0.1 ml). The other patients had general health issues that restricted the use of AmB-D due to the potential risk of systemic toxicity. Seven eyes underwent intravitreal injection of L-AmB (10 μg/0.1 ml) with or without vitrectomy. In these patients, intraocular inflammation and vitreous opacities resolved, and chorioretinal infiltrates evolved into fibrotic scars. Visual acuity improved and stabilized in all eyes during the follow-up period.

Conclusions

Intravitreal L-AmB seems to be well tolerated and effective in the treatment of endogenous candida endophthalmitis, and may be a reasonable alternative for patients who cannot endure the side effects or toxicity associated with conventional AmB-D therapy.
Literature
1.
Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15:414–21.CrossRefPubMed
2.
Parke DW 2nd, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology. 1982;89:789–96.CrossRefPubMed
3.
Donahue SP, Greven CM, Zuravleff JJ, Eller AW, Nguyen MH, Peacock JE Jr, et al. Intraocular candidiasis in patients with candidemia: clinical implications derived from a prospective multicenter study. Ophthalmology. 1994;101:1302–9.CrossRefPubMed
4.
Essman TF, Flynn HW Jr, Smiddy WE, Brod RD, Murray TG, Davis JL, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers. 1997;28:185–94.PubMed
5.
6.
Koç A, Onal S, Yenice O, Kazokoglu H. Pars plana vitrectomy and intravitreal liposomal amphotericin B in the treatment of candida endophthalmitis. Ophthalmic Surg Lasers Imaging. 2010. doi:10.​3928/​15428877-20100215-35.PubMed
7.
Osthoff M, Hilge R, Schulze-Döbold C, Bogner JR. Endogenous endophthalmitis with azole-resistant Candida albicans—case report and review of the literature. Infection. 2006;34:285–8.CrossRefPubMed
8.
Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine. 2003;82:97–105.CrossRefPubMed
9.
Feman SS, Nichols JC, Chung SM, Theobald TA. Endophthalmitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc. 2002;100:67–70.PubMedCentralPubMed
10.
O’Day DM, Head WS, Robinson RD, Stern WH, Freeman JM. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res. 1985;4:131–4.CrossRefPubMed
11.
Fisher JF, Taylor AT, Clark J, Rao R, Espinel-Ingroff A. Penetration of amphotericin B into the human eye. J Infect Dis. 1983;147:164.CrossRefPubMed
12.
Sallam A, Lynn W, McCluskey P, Lightman S. Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther. 2006;4:675–85.CrossRefPubMed
13.
Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, et al. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci. 2003;44:2112–7.CrossRefPubMed
14.
Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987;31:6–10.CrossRefPubMedCentralPubMed
15.
Nomura J, Ruskin J. Failure of therapy with fluconazole for candidal endophthalmitis. Clin Infect Dis. 1993;17:888–9.CrossRefPubMed
16.
Chang YF, Yang CS, Lee FL, Lee SM. Voriconazole for Candida endophthalmitis. Ophthalmology. 2012;119:2414–5.CrossRefPubMed
17.
Shen YC, Wang MY, Wang CY, Tsai TC, Tsai HY, Lee YF, et al. Clearance of intravitreal voriconazole. Invest Ophthalmol Vis Sci. 2007;48:2238–41.CrossRefPubMed
18.
Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52:648–53.CrossRefPubMed
19.
Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92:871–8.CrossRefPubMed
20.
Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs. 1998;55:585–612.CrossRefPubMed
21.
Barza M, Baum J, Tremblay C, Szoka F, D’Amico DJ. Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. Am J Ophthalmol. 1985;100:259–63.CrossRefPubMed
22.
Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105–9.CrossRefPubMed
23.
Martínez-Vázquez C, Fernández-Ulloa J, Bordón J, Sopeña B, de la Fuente J, Ocampo A, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis. 1998;27:1130–3.CrossRefPubMed
Metadata
Title
Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis
Authors
Jeong Hun Bae
Sung Chul Lee
Publication date
01-09-2015
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 5/2015
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-015-0397-x

Other articles of this Issue 5/2015

Japanese Journal of Ophthalmology 5/2015 Go to the issue

Clinical Investigation

Characteristics and surgical outcomes of consecutive exotropia of different etiologies

Laboratory Investigation

Determination of nonsteroidal anti-inflammatory drugs in human tear and plasma samples using ultra-fast liquid chromatography-tandem mass spectrometry

Clinical Investigation

Planned foveal detachment technique for the resolution of diffuse diabetic macular edema

Clinical Investigation

Unilateral medial rectus resection for the treatment of recurrent exotropia in children

Clinical Investigation

Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting

Clinical Investigation

Diurnal intraocular pressure changes in eyes affected with acute primary angle closure and fellow eyes after laser peripheral iridotomy